company background image
4DX

4DMedicalASX:4DX Stock Report

Market Cap

AU$391.7m

7D

-1.8%

1Y

-48.8%

Updated

15 Oct, 2021

Data

Company Financials +
4DX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

4DX Overview

4DMedical Limited operates as a medical technology company in Australia and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for 4DMedical
Historical stock prices
Current Share PriceAU$1.33
52 Week HighAU$1.12
52 Week LowAU$2.70
Beta0
1 Month Change-13.07%
3 Month Change-12.50%
1 Year Change-48.85%
3 Year Changen/a
5 Year Changen/a
Change since IPO-16.35%

Recent News & Updates

Jun 05
Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

4DXAU Healthcare ServicesAU Market
7D-1.8%-0.3%0.1%
1Y-48.8%45.9%19.3%

Return vs Industry: 4DX underperformed the Australian Healthcare Services industry which returned 45.9% over the past year.

Return vs Market: 4DX underperformed the Australian Market which returned 19.3% over the past year.

Price Volatility

Is 4DX's price volatile compared to industry and market?
4DX volatility
4DX Beta0
Industry Beta0.49
Market Beta1

Stable Share Price: 4DX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 4DX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201295Andreas Fourashttps://www.4dmedical.com

4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology that utilizes proven and patented mathematic models and algorithms to convert X-ray scans into quantitative data to enhance the capacity of physicians to manage patients with respiratory diseases and diseases of the lung. The company is also developing VQ (Perfusion), a diagnostic to scan and measure ventilation and perfusion; and Contrast Free Pulmonary Angiography (CFPA) products, as well as small animal ventilators and preclinical scanners.

4DMedical Fundamentals Summary

How do 4DMedical's earnings and revenue compare to its market cap?
4DX fundamental statistics
Market CapAU$391.67m
Earnings (TTM)-AU$21.42m
Revenue (TTM)AU$216.98k

1.8kx

P/S Ratio

-18.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4DX income statement (TTM)
RevenueAU$216.98k
Cost of RevenueAU$91.85k
Gross ProfitAU$125.13k
ExpensesAU$21.55m
Earnings-AU$21.42m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.073
Gross Margin57.67%
Net Profit Margin-9,872.21%
Debt/Equity Ratio0%

How did 4DX perform over the long term?

See historical performance and comparison

Valuation

Is 4DMedical undervalued compared to its fair value and its price relative to the market?

4.7x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4DX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4DX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4DX is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.

PE vs Market: 4DX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4DX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4DX is overvalued based on its PB Ratio (4.7x) compared to the AU Healthcare Services industry average (3.8x).


Future Growth

How is 4DMedical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

20.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4DX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4DX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4DX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4DX's revenue (71.8% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: 4DX's revenue (71.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4DX is forecast to be unprofitable in 3 years.


Past Performance

How has 4DMedical performed over the past 5 years?

-43.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4DX is currently unprofitable.

Growing Profit Margin: 4DX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4DX is unprofitable, and losses have increased over the past 5 years at a rate of 43.9% per year.

Accelerating Growth: Unable to compare 4DX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4DX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).


Return on Equity

High ROE: 4DX has a negative Return on Equity (-25.7%), as it is currently unprofitable.


Financial Health

How is 4DMedical's financial position?


Financial Position Analysis

Short Term Liabilities: 4DX's short term assets (A$85.8M) exceed its short term liabilities (A$8.2M).

Long Term Liabilities: 4DX's short term assets (A$85.8M) exceed its long term liabilities (A$1.1M).


Debt to Equity History and Analysis

Debt Level: 4DX is debt free.

Reducing Debt: 4DX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4DX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4DX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30.3% each year


Dividend

What is 4DMedical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4DX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4DX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4DX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4DX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4DX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Andreas Fouras

no data

Tenure

AU$645,895

Compensation

Dr. Andreas Fouras, BEng, MEngSc(Res), Ph D., M.A.I.C.D., is Founder of 4Dx Limited and serves as its Chief Technology Officer since April 2021, Managing Director and Chief Executive Officer. Dr. Fouras se...


CEO Compensation Analysis

Compensation vs Market: Andreas's total compensation ($USD478.97K) is about average for companies of similar size in the Australian market ($USD551.68K).

Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 4DX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: 4DX's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.2%.


Top Shareholders

Company Information

4DMedical Limited's employee growth, exchange listings and data sources


Key Information

  • Name: 4DMedical Limited
  • Ticker: 4DX
  • Exchange: ASX
  • Founded: 2012
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$391.674m
  • Shares outstanding: 294.49m
  • Website: https://www.4dmedical.com

Number of Employees


Location

  • 4DMedical Limited
  • 468 St Kilda Road
  • Suite 501
  • Melbourne
  • Victoria
  • 3004
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 15:52
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.